Probiotics and Synbiotics—Options to Manage Infections with Multi-Drug Resistant Bacteria?

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Antimicrobial Agents and Resistance".

Deadline for manuscript submissions: closed (20 November 2021) | Viewed by 2596

Special Issue Editor


E-Mail Website
Guest Editor
Faculty of Health Sciences, Calisia University, 62-800 Kalisz, Poland
Interests: probiotics; gut microbiota; antimicrobial activity; pathogen overgrowth; Clostridium infections
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Antibiotic resistance has become a major concern worldwide. Bacteria with a broad range of resistance against antibiotics are spreading at an alarming rate. Hospitals, and in particular intensive care units, are proliferation zones for multi-drug-resistant bacteria. The first bacterial strains have emerged that are resistant against all available antibiotics. The steady trend of increasing resistance coupled with the lack of new antibiotic developments targeting resistant bacteria is forcing clinicians to apply more aggressive antibiotic dosing regimens, such as prolonged administration and combinations of different antibiotics. However, this increase in antibiotic utilization may not be the solution, and might instead add to the problem. While good antibiotic stewardship is one important pillar in limiting antibiotic resistance development, new non-antibiotic strategies have to be considered for the management of infections with multi-drug-resistant bacterial pathogens. Colonization resistance provided by a balanced and diverse gut microbiota is a well-known mechanism to keep the spread of bacterial pathogens under control in the human body. The administration of pro- or synbiotics is a promising strategy to support this natural mechanism. Prophylactic administration of probiotic bacteria as well as administration in combination with antibiotics have to be considered. While there are first promising data showing the value of pro- and synbiotics in the management of infections with multi-drug-resistant infection, more research is needed to establish a better understanding of the potential role of probiotic microorganisms in this challenging task of healthcare.

Dr. Jacek Piatek
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gut microbiota
  • probiotics
  • synbiotics
  • gut colonization resistance
  • multi-drug resistance
  • pathogen inhibition
  • nosocomial infections
  • post-antibiotic era

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 806 KiB  
Article
Nine-Strain Bacterial Synbiotic Improves Crying and Lowers Fecal Calprotectin in Colicky Babies—An Open-Label Randomized Study
by Malgorzata Bernatek, Jacek Piątek, Marcin Pszczola, Hanna Krauss, Janina Antczak, Paweł Maciukajć and Henning Sommermeyer
Microorganisms 2022, 10(2), 430; https://doi.org/10.3390/microorganisms10020430 - 12 Feb 2022
Cited by 2 | Viewed by 1935
Abstract
The aim of this study (ClinicalTrials.gov registration NCT04666324) was to determine the effects of a nine-strain synbiotic and simethicone on the duration of crying and the gut inflammation marker calprotectin in colicky babies aged 3–6 weeks, diagnosed using the Wessel criteria. The open-label [...] Read more.
The aim of this study (ClinicalTrials.gov registration NCT04666324) was to determine the effects of a nine-strain synbiotic and simethicone on the duration of crying and the gut inflammation marker calprotectin in colicky babies aged 3–6 weeks, diagnosed using the Wessel criteria. The open-label study comprised a control group of non-colicky babies (n = 20) and two parallel treatment groups (each n = 50) to which colicky babies were randomly and equally assigned to receive the multi-strain synbiotic or simethicone orally for 28 days. Primary outcome measures were the change in daily crying duration and the level of fecal calprotectin on days 1 and 28 of the study. Administration of the synbiotic resulted in a rechange of crying duration of −7.18 min/day of treatment, while simethicone had a significantly smaller effect (−5.74 min/day). Fecal calprotectin levels in colicky babies were significantly elevated compared to those in non-colicky babies. Treatment with the nine-strain synbiotic resulted in a significant lowering of fecal calprotectin at the end of the study, while no such effect was found for simethicone. No adverse effects were reported. Study results confirm earlier findings of crying duration reductions in colicky babies by the synbiotic, an effect that might be linked to its anti-inflammatory properties. Full article
Show Figures

Figure 1

Back to TopTop